Krystal Biotech, Inc.
NASDAQ:KRYSBiotechnology
+$18.29 today
- Market cap
- $9.34B
- Beta
- 0.53
- P/E (TTM)
- 44.5
- EPS (TTM)
- $7.68
Volume 0.35M
Average 0.29M
KRYS Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Krystal Biotech, Inc.NASDAQ: KRYS
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income grows, but more slowly than its trailing trend
Q2 FY2026 net income of $54.77M rose 42.9% year over year, behind the +64.6% change in trailing-twelve-month net income. Sequentially, it fell 2.1% from the prior quarter.
Context
- Net income amounted to 52.6% of revenue in FY2025, up 21.9 pp from a year earlier.
- Net income increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of $232.86M (+13.7%) for the fiscal year ending Dec 2026, a slowdown from the +129.7% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $54.77M-2.1% QoQ
- Last fiscal yearDec 2025
- $204.83M+129.7% YoY
- LTMJun 2026
- $241.47M+64.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +42.9% | -30.5% | -73.4 pp |
| 1 year | +129.7% | +13.7% | -116.1 pp |
| 3-year CAGR | — | +25.7% | — |
| 5-year CAGR | +35.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 204.83M USD
- Year-over-year change
- +129.7%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 204.83M | +129.7% |
| FY2024 | 2024-12-31 | 89.16M | +715.6% |
| FY2023 | 2023-12-31 | 10.93M | +107.8% |
| FY2022 | 2022-12-31 | (139.98M) | -101.2% |
| FY2021 | 2021-12-31 | (69.57M) | — |
Net Income vs competitors
How KRYS compares with its peers on the latest reported figures
- KRYS's LTM Jun 2026 net income of $241.47M is the 4th largest of the 6 companies compared; the peer median is $241.99M.
- Its year-over-year change of +64.6% is the 4th highest of 6, against a peer median of +83.9%.
- Net income amounts to 54.8% of revenue for KRYS, versus a peer median of 412.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $328.6M | +96.4% | -4.1% | 412.0% | |
| LTM Mar 2026 | $290.01M | +83.9% | -11.6% | 330.2% | |
| LTM Mar 2026 | $241.99M | +16.0% | -3.2% | — | |
| LTM Jun 2026 | $241.47M | +64.6% | — | 54.8% | |
| LTM Mar 2026 | $209.38M | -18.9% | +0.2% | — | |
| LTM Mar 2026 | $66.14M | +249.7% | — | 454.9% | |
| Peer median (excluding KRYS) | $241.99M | +83.9% | -3.7% | 412.0% | |
Competitors are the stored peer set for KRYS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (69.57M) | (139.98M) | 10.93M | 89.16M | 204.83M |
| Depreciation & Amortization | 2.77M | 4.05M | 5.01M | 6.71M | 6.55M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | (22.85M) |
| Stock-Based Compensation | 15.32M | 33.23M | 39.93M | 49.13M | 54.51M |
| Change in Working Capital | 2.05M | 2.81M | (37.88M) | (14.46M) | (36.42M) |
| Accounts Receivables | 0 | 0 | (42.04M) | (62.71M) | (22.12M) |
| Inventory | 0 | 0 | (4.48M) | (11.91M) | (6.29M) |
| Accounts Payables | 712K | (1.25M) | (101K) | 1.01M | 826K |
| Other Working Capital | 1.34M | 4.07M | 8.73M | 59.15M | (8.84M) |
| Other Non-Cash Items | 1.49M | (690K) | (106.79M) | (7.12M) | (5.77M) |
| Operating Cash Flow | (47.94M) | (100.57M) | (88.8M) | 123.42M | 200.87M |
| Capital Expenditures | (68.34M) | (52.98M) | (11.8M) | (4.24M) | (11.95M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 435K |
| Purchases of Investments | (190.46M) | (318.78M) | (508.78M) | (457.74M) | (422.54M) |
| Sales of Investments | 32.03M | 257.68M | 503.21M | 298.54M | 375.64M |
| Other Investing Activities | 0 | 0 | 100M | 0 | 0 |
| Investing Cash Flow | (226.77M) | (114.08M) | 82.64M | (163.44M) | (58.42M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 355.65M | 36M | 203.5M | 32.4M | 22.66M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (7.96M) | (649K) | (749K) | (5.39M) | (13.96M) |
| Financing Cash Flow | 347.69M | 35.35M | 202.75M | 27.01M | 8.71M |
| Effect of Forex Changes | 0 | (41K) | (156K) | (458K) | 286K |
| Net Change in Cash | 72.98M | (179.35M) | 196.43M | (13.46M) | 151.44M |
| Free Cash Flow | (116.27M) | (153.55M) | (100.6M) | 119.18M | 188.91M |
Krystal Biotech, Inc.
NASDAQ:KRYS
Intrinsic Alpha fair value
Locked
Current Price
$315.34
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.